Teriparatide biosimilar - BiosidusAlternative Names: Osteofortil; Recombinant teriparatide - Biosidus
Latest Information Update: 26 Sep 2013
At a glance
- Originator Biosidus S.A.
- Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoporosis
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 30 Sep 2012 Launched for Osteoporosis in Argentina (Parenteral)